Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine Extended Treatment for Bipolar I Manic/Mixed Episodes
NCT00266630Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2005
- Primary completion
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of olanzapine in bipolar I disorder (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Change From Baseline to Endpoint in Young Mania Rating Scale Total Scores at 18 weeks, Number of Participants With Response of Manic Symptoms at 18 weeks and 2 more. Started Nov 2005; status: completed.
02
Drugs
olanzapine
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on NCT00266630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00266630.